PITTSBURGH, Sept. 1 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched levalbuterol inhalation solution USP (Concentrate), 0.25%, (1.25 mg/0.5 mL). Mylan, which has already launched the product, will market this product with 180 days of exclusivity.
This product, which is indicated for the treatment or prevention of bronchospasm in patients over 6 years old with reversible obstructive airway disease, is the first generic version of Sepracor Inc.'s Xopenex(R) Inhalation Solution (Concentrate), 0.25%, to be approved by the U.S. Food and Drug Administration (FDA). According to IMS Health, Xopenex Inhalation Solution (Concentrate), 0.25% had total U.S. sales of approximately $18.3 million for the 12 months ending June 30, 2009.
Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; operates a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.
|SOURCE Mylan Inc.|
Copyright©2009 PR Newswire.
All rights reserved